Teva’s New York Opioid Liability Climbs To $523m With Settlement Deal
President And CEO Kåre Schultz: ‘We Are Quite Satisfied With Outcome’
Executive Summary
Teva is on the hook to pay more than $300m to New York state over the next 18 years, in addition to $210m in damages already agreed under its proposed nationwide settlement deal, after settling claims with the New York Attorney General.
You may also be interested in...
Five Big Legal Stories From 2022
Generics Bulletin looks back at a selection of the most significant legal stories from 2022, including a major victory in the UK on the Eliquis blood thinner giant and continued action on generic label carve outs, which has the potential to reverberate through the US industry.
Long-Awaited Nationwide Opioid Settlement To Move Forward For Teva
Teva has all but two US states on board for its long-hoped-for nationwide settlement to resolve opioid-related claims against the firm.
Five Things Facing Teva’s New CEO Richard Francis
With Teva clearing up early who will replace outgoing president and CEO Kåre Schultz, Generics Bulletin looks at five issues that await his replacement, the former Sandoz head Richard Francis.